학술논문

2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: A randomised, Phase 3 trial
Document Type
Article
Source
In: The Lancet Oncology. (The Lancet Oncology, February 2013, 14(2):117-124)
Subject
Language
English
ISSN
14702045
14745488